Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 6

de to respond to a delication of information arises it displays a valid emis dention number.					
Confirmation Number	7706				
Application Number	10/813,965				
Filing Date	March 31, 2004				
First Named Inventor	Robert Falotico				
Group Art Unit	1617				
Examiner Name	Jennifer Kim				
Attorney Docket Number	CRD5073USNP				

U.S. PATENT DOCUME	ENTS
--------------------	------

		U.S. Patent Document			D	D 01 1:
Exam Initials	Cite No. ¹		d Code ² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		3,929,992		Sehgal et al.	12-30-1975	
		3,959,078		Guire et al.	05-25-1976	
		4,350,160		Kolesov	09-21-1982	
		4,366,819		Kaster	01-04-1983	
		4,368,736		Kaster	01-18-1983	
		4,624,257		Berggren et al.	11-25-1986	
		4,722,906		Guire et al.	02-02-1988	

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant	
Exam Initials	Cite No. ¹	Office ³	Number ⁴ KindCod	e^5	Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T ⁶
		WO	04/011000	Α	Wyeth	02-05-2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²						
*									
		AJROLDI et al., "Fluoroelastomers-dependence of relaxation phenomena on compositions",							
		Polymer 30, 2180 (1989)							
		ARCELLA, V. et al., "Fluorocarbon Elastomers", Modern Fluoropolymers, (J. Shires ed.), John							
		Wiley & Sons, New York, pp. 77-87 (1997)							
		BERK, B.C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis							
		After", J. Am. College Cardiology 17: 111B-117B (1991)							
		CARRERA et al., "Potent Toxicity of 2-Chlorodeoxyadenosine toward Human Monocytes in Vitro							
		and In Vivo" J. Clin. Invest. 86: 1480-1488 (1990)							
		CARSON, D.A. et al., "Specific toxicity of 2-chlorodeoxyadenosine toward resting and							
		proliferating human lymphocytes", <u>Blood</u> 62: 737-743 (1983)							
		CHANG, M. W. et al., "Adenovirus-mediated Over-expression" J. Clin. Invest. 96: 2260-2268							
		(1995)							
Examine Signatur		Date Considered							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 6

d to respond to a collection of information unless it displays a valid OMB control number					
Confirmation Number	7706				
Application Number	10/813,965				
Filing Date	March 31, 2004				
First Named Inventor	Robert Falotico				
Group Art Unit	1617				
Examiner Name	Jennifer Kim				
Attorney Docket Number	CRD5073USNP				

U.S. PATENT DOCUMENTS

Even Cite		U.S. Patent Document			Date of Publication	Pages, Columns, Lines,
Exam Initials	Cite No. ¹		l Code ² .nown)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		4,733,665		Palmaz	03-29-1988	
		4,739,762		Palmaz	04-26-1988	
		4,776,337		Palmaz	10-11-1988	
		4,917,090		Berggren et al.	04-17-1990	
		4,917,091		Berggren et al.	04-17-1990	
		5,229,172		Cahalan et al.	07-20-1993	
		5,234,447		Kaster et al.	08-10-1993	

FOREIGN PATENT DOCUMENTS

l			Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant			
ı	Exam Initials	Cite No. ¹	Office ³	Number ⁴	KindCode	e ⁵	Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T ⁶
ı										

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CLOWES, A. W. et al. "Suppression by heparin of smooth" Nature 265: 625-626 (1977)	
		CLOWES, A.W. et al. "Kinetics of Cellular Proliferation" <u>Lab. Invest.</u> 52: 611-616 (1985)	
		CLOWES, A.W. et al., "Kinetics of Cellular Proliferation" Circ. Res. 58: 839-845 (1986)	
		COLBURN, M.D. et al., "Done responsive suppression of" J. Vasc. Surg. 15: 510-518 (1992)	
		CURRIER, J.W. et al., <u>Circ.</u> 80: 11-66 (1989)	
		DEROANNE, C.F. et al., "Histone deacetylases inhibitors", Oncogene 21 (3): 427-436 (2002)	
		FARB, A. et al., "Vascular Smooth Muscle Cell Cytotoxicity", Circ. Res. 80: 542-550 (1997)	

Examiner	Date	
Signature	Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 6

a to respond to a collection of information driless it displays a valid SWIB control number.					
Confirmation Number	7706				
Application Number	10/813,965				
Filing Date	March 31, 2004				
First Named Inventor	Robert Falotico				
Group Art Unit	1617				
Examiner Name	Jennifer Kim				
Attorney Docket Number	CRD5073USNP				

U.S. PATENT DOCUMENTS

		U.S. Patent Documer	nt		Date of Publication	Doggo Columno Lines
Exam Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		5,308,641		Cahalan et al.	05-03-1994	
		5,350,800		Verhoeven	09-27-1994	
		5,415,938		Cahalan et al.	05-16-1995	
		5,837,313		Ding et al.	11-17-1998	
		6,099,562		Ding et al.	08-08-2000	
		6.120.536		Ding et al.	09-19-2000	

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant	
Exam Initials	Cite No. ¹	Office ³	Number⁴ KindCoo	le ⁵	Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FERNS, G.A.A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation after	
		Angioplasty", <u>Science</u> 253: 1129—1132 (1991)	
		FUKUYAMA, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon	
		injury" <u>Eur. J. Pharmacol.</u> 318: 327-332 (1996)	
		GUYTON, J.R. et al., "Inhibition of Rat Arterial Smooth Muscle" Circ. Res. 46: 625-634 (1980)	
		HANSON, S.R. et al, "Interruption of acute platelet-dependent thrombosis by the synthetic"	
		Proc. Natl. Acad. Sci. USA 85: 3184-3188 (1988)	
		HANSSON, G.K. et al., "Interferon-γ Inhibits Arterial Stenosis" Circ. 84: 1266-1272 (1991)	
		JONASSON, L. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular	
		response to injury" Proc. Natl. Acad. Sci. 85: 2303 (1988)	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 4 of 6

d to respond to a collection of information unless it displays a valid OMB control hum						
Confirmation Number	7706					
Application Number	10/813,965					
Filing Date	March 31, 2004					
First Named Inventor	Robert Falotico					
Group Art Unit	1617					
Examiner Name	Jennifer Kim					
Attorney Docket Number	CRD5073USNP					

U.S. PATENT DOCUMENTS

					OIGH ATENT BOOGHERITO		
Exam Initials	Cite No. ¹	U.S. Patent Docume	Kind Code ²		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

					Foreign	Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant	
Exam Initials	Cite No. ¹	Office ³	Number ⁴ KindCoo	le ⁵	Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T ⁶			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LIU, M.W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the	
		Atherosclerotic Rabbit" Circ. 81: 1089-1093 (1990)	
		LUNDERGAN, C.F. et al., "Peptide Inhibition of Myointimal Proliferation by Angiopeptin"	
		<u>Am. J. Cardiol.</u> 17 (Suppl. B): 132B-136B (1991)	
		MAJESKY, M.W. et al., "Heparin Regulates Smooth Muscle S Phase Entry In the Injured Rat	
		Carotid Artery" <u>Circ. Res.</u> 61: 296-300 (1987)	
		MARX, S.O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation In Vascular	
		Smooth Muscle Cells" Circ. Res. 76: 412-417 (1995)	
		NEMECEK, G.M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth	
		Factor in Vitro and Neointimal Proliferation in Vivo" J. Pharmacol. Exp. Thera. 248: 1167-1174	
		(1989).	

Examiner	Date	
	Date	
Signature	Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 5 of 6

ed to respond to a collection of information driless it displays a valid OMB control fluin						
Confirmation Number	7706					
Application Number	10/813,965					
Filing Date	March 31, 2004					
First Named Inventor	Robert Falotico					
Group Art Unit	1617					
Examiner Name	Jennifer Kim					
Attorney Docket Number	CRD5073USNP					

U.S. PATENT DOCUMENTS

					OIGH ATENT BOOGHERITO		
Exam Initials	Cite No. ¹	U.S. Patent Docume	Kind Code ²		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

		. or -3 N1 -4 16-40-4-5		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant	
Exam Initials	Cite No. ¹			Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		OKADA, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation After Endothelial Injury without Systemic Anticoagulation" Neurosurgery 25: 892-898 (1989)	
		POWELL, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury" <u>Science</u> , 245: 186-188 (1989)	
		SIMONS, M. et al., "Antisense <i>c-myb</i> oligonucleotides inhibit intimal arterial smooth muscle sell accumulation <i>in vivo</i> " <u>Nature</u> 359: 67-70 (1992)	
		SNOW, A.D. et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding" Am. J. Pathol. 137: 313-330 (1990)	
		SOLLOT, S.J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty in the Rat" J. Clin. Invest. 95: 1869-1876 (1995)	
		WEINBERGER, J. et al., "Intracoronary Irradiation: Dose response For The Prevention of Restenosis in Swine" Int. J. Rad. Onc. Biol. Phys. 36: 767-775 (1996)	
		WOO, S.H. et al., "Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors" <u>J. Med Chem</u> , 45: 2877-2885 (2002)	

Examiner	Date
Signature	Considered

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.